Cannabis Science Operational Update: First Data from Preclinical Development Expected This Week; Cannabis Science Plans to Open Informational Hotline for General Public
COLORADO SPRINGS, Colo., June 2, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in the development of cannabis based medicine is very pleased to announce that the first set of data from the preclinical development of proprietary cannabinoid-based product is expected this week. The product development for neurological disorders is one of the many applications the Company is developing under the patent filed last year.
In response to the numerous communications that the Company receives from the general public about medical cannabis research and treatment for critical ailments, Cannabis Science intends to establish an informational hotline in the near future to respond in real time to questions and to provide educational information about cannabinoid-based products.
Co-Founder of Cannabis Science Inc., Professor Robert J. Melamede, Ph.D. and his Cannabis Science business partner, Raymond C. Dabney, also an original Co-Founder of Cannabis Science, announce that Professor Melamede's personal health challenges have prompted an immediate decision to retire from his extensive day-to-day operational duties while continuing to work with Cannabis Science as a member of the Company's Scientific Advisory Board. Professor Melamede is also retiring from his position at the University of Colorado, Colorado Springs (UCCS), where he held the role of Chairman and Tenured Associate Professor. In conjunction with his retirement by agreement with Mr. Dabney, Dr. Melamede has sold all of his Series A preferred voting shares of Cannabis Science to the Bogat Family Trust, Raymond C. Dabney, Trustee.
"The best is yet to come. I am proud to see Cannabis Science building on its scientific leadership in the industry, excited to see the new data, and applaud the hotline. Communication is key to progress. I look forward to continuing to work with the Company's team and to contributing scientific expertise in the years ahead," stated Dr. Melamede, President Emeritus and Member of the Scientific Advisory Board, Cannabis Science, Inc.
Dr. Bray, President & CEO of Cannabis Science Inc., stated, "We wish Dr. Bob speedy improvement in his health condition. As we begin to receive data from the pre-clinical development of our products, we are delighted that Dr. Bob will continue to support us with his passion in creating multiple relationships and collaborative business links for Cannabis Science."
"Dr. Bob," as he is affectionately referred to, has become an icon to the cannabis industry during the last 40 years. He has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York, also pursuing academics at New York Medical College and the University of Vermont prior to moving to Colorado. Professor Melamede began his formal activist and political pursuits in Vermont, including running for U.S. Senate in 1994, U.S. House of Representatives in 1996, and U.S. Senate again in 1998. Professor Melamede is an authority on the therapeutic uses of cannabis and the study of the endocannabinoid system. In recognition of his contribution over the years, the Company has awarded Dr. Bob with the title of "Cannabis Science President Emeritus".
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.